The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Cell Sheet-Based Gene Therapy Market At The End Of The 2026–2030 Forecast Period?
The cell sheet-based gene therapy market has seen rapid growth in recent years. Its value is projected to increase from $0.68 billion in 2025 to $0.78 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.4%. This growth in the preceding period can be attributed to several factors, such as increasing advancements in tissue engineering research, the early adoption of regenerative medicine techniques, a rise in cell-based therapeutic studies, improvements in gene delivery technologies, and the expansion of translational research initiatives.
The cell sheet-based gene therapy market size is projected to undergo rapid expansion in the upcoming years. It is foreseen to attain $1.34 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.6%. This anticipated growth throughout the forecast period stems from escalating demand for localized regenerative therapies, an increase in clinical trials involving gene-modified cell therapies, the broadening of oncology and cardiology applications, expanding investments in advanced tissue engineering, and a heightened focus on precision regenerative medicine. Prominent trends for the forecast period include the advancement of multilayered and co-culture cell sheet technologies, an increasing emphasis on localized gene expression therapies, the growing incorporation of regenerative medicine approaches, enhanced utilization of stem-cell derived cell sheets, and a stronger focus on tissue integration and longevity.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33058&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Cell Sheet-Based Gene Therapy Market?
An increasing incidence of chronic and degenerative conditions is anticipated to fuel expansion within the cell sheet-based gene therapy market. These long-term ailments, which encompass cardiovascular ailments, neurodegenerative illnesses, diabetes, and genetic conditions, lead to gradual harm to tissues and organs, necessitating ongoing treatment. The growing occurrence of these diseases stems from an aging global population and enhanced life expectancy in both mature and emerging economies. Cell sheet-based gene therapy offers regenerative treatment options for chronic and degenerative conditions by facilitating localized tissue repair and continuous gene delivery via stacked living cell structures, thereby enhancing tissue integration and enduring treatment benefits. As an illustration, the International Diabetes Federation (IDF), a non-profit organization based in Belgium, reported in April 2025 that 589 million individuals globally had diabetes in 2024, with this number forecast to escalate to 853 million by 2050. Consequently, the increasing occurrence of chronic and degenerative diseases is propelling the expansion of the cell sheet-based gene therapy market.
What Segment Types Make Up The Cell Sheet-Based Gene Therapy Market?
The cell sheet-based gene therapy market covered in this report is segmented –
1) By Cell-Sheet Type: Monolayer Cell-Sheet Type; Co-Culture Cell-Sheet Type; Multilayered Cell-Sheet Type; Other Cell-Sheet Types
2) By Technology Type: Cell Sheet-Based Engineering Techniques; Gene Delivery Methods
3) By Source Type: Autologous; Allogenic; Stem-Cell Derived
4) By Application: Oncology; Ophthalmology; Genetic Disorders; Cardiology; Other Applications
5) By End-User: Hospitals And Clinics; Research And Academic Institutions; Biotech And Pharma Companies; Other End-Users
Subsegments:
1) By Monolayer Cell-Sheet Type: Cardiomyocyte Sheets; Epithelial Cell Sheets; Mesenchymal Stem Cell Sheets; Other Monolayer Cell Sheets
2) By Co-Culture Cell-Sheet Type: Fibroblast + Stem Cell Sheets; Endothelial + Smooth Muscle Cell Sheets; Other Co-Culture Combinations
3) By Multilayered Cell-Sheet Type: Triple-Layered Sheets; Double-Layered Sheets; Other Multilayered Configurations
4) By Other Cell-Sheet Types: Genetically Modified Cell Sheets; Hybrid Cell Sheets; Other Novel Or Experimental Sheets
Which Market Trends Are Creating New Opportunities In The Cell Sheet-Based Gene Therapy Market?
Within the cell sheet-based gene therapy market, leading companies are concentrating on creating advanced solutions, including autologous gene-corrected cell sheet products. These efforts aim to improve regenerative medicine results, increase treatment accuracy, and achieve lasting tissue repair through the integration of engineered cells with scaffold-free sheet constructs for precise gene delivery and wound treatment. Autologous gene-corrected cell sheet products denote therapies involving a patient’s own cells, which are genetically altered outside the body, expanded into sheet structures maintaining cell interactions and extracellular matrix integrity, and then directly applied to injured tissues to foster functional integration and sustained therapeutic benefits. An example of this is the approval granted in April 2025 to Abeona Therapeutics Inc., a US-based biopharmaceutical company, by the Food and Drug Administration (FDA), a US-based federal agency. This approval was for zevaskyn (prademagene zamikeracel), a treatment developed for wounds in both adult and pediatric patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn works by delivering the functional COL7A1 gene using genetically corrected cell sheets, leading to significant wound healing and pain reduction with just one application, while also supporting continuous type VII collagen expression at wound sites. This establishes it as a pioneering regenerative therapy and a benchmark for subsequent innovations in cell sheet-based gene therapy.
Who Are The Leading Companies Operating In The Cell Sheet-Based Gene Therapy Market?
Major companies operating in the cell sheet-based gene therapy market are Hitachi Ltd., Thermo Fisher Scientific, Fujifilm Cellular Dynamics Inc. (FCDI) (FUJIFILM Holdings Corporation), Lonza Group AG, teijin regenet co. ltd., Terumo Corporation, Nikon CeLL innovation Co. Ltd., Rohto Pharmaceutical Co. Ltd., BioBridge Global, AGC Biologics, Shibuya Corporation (Shibuya Kogyo Co. Ltd.), National Resilience Inc., Takara Bio Inc., Japan Tissue Engineering Co. Ltd. (J-TEC), Medipost Co. Ltd., Cell Therapies Pty Ltd, CellSeed Inc., SCTbio, Abeona Therapeutics Inc., Foundation ENEA Tech, Cyto-Facto Inc., ENCELL Co. Ltd.
Read the full cell sheet-based gene therapy market report here:
https://www.thebusinessresearchcompany.com/report/cell-sheet-based-gene-therapy-market-report
Which Region Is Projected To Lead The Cell Sheet-Based Gene Therapy Market During The Forecast Period?
North America was the largest region in the cell sheet based gene therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell sheet-based gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Cell Sheet-Based Gene Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=33058&type=smp
Browse Through More Reports Similar to the Global Cell Sheet-Based Gene Therapy Market 2026, By The Business Research Company
Cell And Gene Therapy Clinical Trial Services Market Report 2026
Cell And Gene Therapy Manufacturing Services Market 2026
Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model